Tyra Biosciences stock hits 52-week low at $11.88 amid market shifts

In a challenging year for biotech firms, Tyra Biosciences’ stock has touched a 52-week low, with shares falling to $11.88. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $28 to $33, suggesting significant potential upside. The company, known for its innovative approach to precision medicine, has not been immune to the broader market trends that have seen investor confidence waver in the sector. Over the past year, Tyra Biosciences has experienced a significant downturn in its stock value, with a 1-year change showing a decline of 40.2%. Despite market challenges, the company maintains a strong financial health score and holds more cash than debt on its balance sheet. With earnings scheduled for March 19, investors seeking deeper insights can access 7 additional exclusive ProTips on InvestingPro. This latest price level reflects investor sentiment and market dynamics that continue to test the resilience of biotech stocks amidst a volatile economic landscape.

In other recent news, Tyra Biosciences has received attention following the presentation of its Phase 1 TYRA-300 data at the 2025 American Society of Clinical Oncology Genitourinary conference. H.C. Wainwright reaffirmed its Buy rating and maintained a $30 price target for Tyra Biosciences, citing TYRA-300’s leading position as a Fibroblast Growth Factor Receptor 3 (FGFR3) inhibitor. The firm highlighted concerns about Eli Lilly (NYSE:LLY)’s FGFR3-selective inhibitor, LY3866288, which showed higher toxicity rates and less favorable dosing compared to TYRA-300. Meanwhile, Tyra Biosciences announced the appointment of Adele Gulfo to its Board of Directors. Gulfo’s extensive experience in the pharmaceutical industry is expected to provide valuable guidance as the company advances its drug development efforts. Additionally, Tyra Biosciences received FDA clearance to proceed with a Phase 2 clinical trial for TYRA-300, targeting non-muscle invasive bladder cancer. UBS initiated coverage on Tyra Biosciences with a Buy rating and a $28 price target, expressing optimism about the long-term growth potential of TYRA-300 in oncology and growth disorders. The UBS analyst’s projections suggest significant revenue potential for the company, driven by its innovative drug pipeline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.